Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.41 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6935269 | 0.99 | GRIN1 (0.45) | GRIN1GRIN2BTGFBR1NPC1RAB9A | |
| SCHEMBL5790262 | 0.84 | MAPK14 (0.45) | GRIN1GRIN2BTGFBR1NPC1RAB9A | |
| SCHEMBL6933561 | 0.84 | TGFBR1 (0.43) | GRIN1GRIN2BTGFBR1NPC1RAB9A | |
| SCHEMBL5788057 | 0.84 | TGFBR1 (0.43) | GRIN1GRIN2BTGFBR1NPC1RAB9A | |
| SCHEMBL6933563 | 0.84 | GRIN1 (0.43) | GRIN1GRIN2BTGFBR1NPC1RAB9A | |
| SCHEMBL5787744 | 0.83 | CSNK1D (0.55) | TGFBR1NPC1RAB9AMAPK14MAPK11 | |
| SCHEMBL5847952 | 0.82 | MAPK9 (0.43) | TGFBR1NPC1RAB9AMAPK14MAPK11 | |
| SCHEMBL5791511 | 0.80 | MAPK9 (0.47) | GRIN1GRIN2BTGFBR1NPC1RAB9A | |
| SCHEMBL27507564 | 0.80 | MAPK9 (0.49) | MAPK14MAPK9MAPK13MAPK12MAP4K4 | |
| SCHEMBL4826188 | 0.79 | MAPK9 (0.56) | MAPK14MAPK11MAPK9MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448564-B1 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6921762-B2 | Substituted indolizine-like compounds and methods of use | AMGEN INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1448564-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6649604-B2 | Analgesics; antidiabetic agents; antiinflamamtory agents | AMGEN INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003044021-A2 | SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195221-A1 | Substituted indolizine-like compounds and methods of use | IL1A, IL1B, IL6 | GRIN1 1416/4885GRIN2B 3786/4885TGFBR1 2560/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | GRIN1 2583/4885GRIN2B 3749/4885TGFBR1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.